Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Feb 1.

Published in final edited form as: Cancer Biol Ther. 2010 Feb 25;9(3):236–242. doi: 10.4161/cbt.9.3.10749

Fig. 3 — Total RNA was extracted from MIA-V, MIA-ZIP4, ASPC-shV, and ASPC-shZIP4 xenografts and the mRNA level for VEGF was analyzed by real time PCR, and normalized to that of the house keeping gene, β-actin. Relative mRNA level is presented as fold change compared with the vector control. A. Relative VEGF mRNA level in MIA-V and MIA-ZIP4 subcutaneous xenografts. B. Relative VEGF mRNA level in MIA-V and MIA-ZIP4 orthotopic xenografts. C. Relative VEGF mRNA level in ASPC-shV and ASPC-shZIP4 orthotopic xenografts. All data shown are the mean±SD of three separate experiments. *p < 0.05.

Fig. 3 — Total RNA was extracted from MIA-V, MIA-ZIP4, ASPC-shV, and ASPC-shZIP4 xenografts and the mRNA level for VEGF was analyzed by real time PCR, and normalized to that of the house keeping gene, β-actin. Relative mRNA level is presented as fold change compared with the vector control. A. Relative VEGF mRNA level in MIA-V and MIA-ZIP4 subcutaneous xenografts. B. Relative VEGF mRNA level in MIA-V and MIA-ZIP4 orthotopic xenografts. C. Relative VEGF mRNA level in ASPC-shV and ASPC-shZIP4 orthotopic xenografts. All data shown are the mean±SD of three separate experiments. *p < 0.05.

HHS Vulnerability Disclosure